Skip to main content
. Author manuscript; available in PMC: 2010 Dec 14.
Published in final edited form as: Clin Cancer Res. 2009 Dec 15;15(24):7593–7601. doi: 10.1158/1078-0432.CCR-09-2317

FIGURE 6. Hyaluronan oligomer treatment inhibits growth of CD133-hi ovarian carcinomas in vivo.

FIGURE 6

104 CD133-hi cells, obtained by magnetic sorting for CD133, were injected in Matrigel into the peritoneum of SCID mice at day 0. Beginning one week after injection of cells, PBS (200μl) or hyaluronan oligomers (500μg; 25mg/kg) in PBS were injected intraperitoneally once per week for 6 weeks. A. Tumor growth, as assessed by percent change in weight due to ascites accumulation, was calculated as in Fig. 1C. B. Numbers of cells that accumulated intraperitoneally after 7 weeks. Error bars express standard deviation in the mean of results from 4 or more animals. Significant differences were observed between treated and untreated animals (A: *p<.05; B: **p<.01) as determined by Student's t-test.